hdac  (BPS Bioscience)

Journal: Clinical and Translational Medicine

Article Title: Natural HDAC‐1/8 inhibitor baicalein exerts therapeutic effect in CBF‐AML

doi: 10.1002/ctm2.154

Figure Lengend Snippet: Effects of Baicalein on HDAC‐1/8 activity and the expression of HDAC inhibitors‐associated ABC transporter genes. A, HDACs enzyme activity assay of Baicalein and TSA. B, ME‐1 cells were treated with Baicalein (30 µM) for 6 h. The temperatures were between 37 and 70°C and used to perform ITDR CETSA assay directed toward HDAC‐1, HDAC‐2, HDAC‐3, and HDAC‐8. Data were first normalized by setting the highest and lowest value in each set to 100% and 0%, respectively. Data were obtained in the presence of the Baicalein (red square) as positive control and DMSO (blue circle) as negative control. C, Primary AML cells (#2, #15, #24, #38) were treated with 165 nM TSA or 3 mM VPA for 24 h or 30 µM Baicalein for 96 h. The accumulation of Rh‐123 were detected by flow cytometry. D, Kasumi‐1, ME‐1 cells, and primary AML cells (#1, #2, #28) were treated with 165 nM TSA or 3 mM VPA for 24 h or 30 µM Baicalein for 96 h. Effects of HDAC inhibitors on MDR1 , MRP7 , MRP8 , and BCRP expression were analyzed by RT‐qPCR. The data represent the mean ± SD of three different experiments. Asterisks denote statistically significant * P < .05; ** P < .01; Differences compared with controls by one‐way ANOVA

Article Snippet: The substrate of HDAC‐1 (#50051, BPS Bioscience, California, USA), HDAC‐2 (KDA‐21‐277, Reaction Biology Corp internally, Pennsylvania, USA), and HDAC‐3 (#50003, BPS Bioscience, California, USA) were K379‐382 (RHKK(Ac)AMC) residues of p53.

Techniques: Activity Assay, Expressing, Enzyme Activity Assay, Positive Control, Negative Control, Flow Cytometry, Quantitative RT-PCR